Carrier Screening Market Size, Share & Trends Analysis Report By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), By Medical Condition, By Technology, By Region, And Segment Forecasts, 2023 - 2030

Carrier Screening Market Size, Share & Trends Analysis Report By Type (Expanded Carrier Screening, Targeted Disease Carrier Screening), By Medical Condition, By Technology, By Region, And Segment Forecasts, 2023 - 2030

Carrier Screening Market Growth & Trends

The global carrier screening market size is expected to reach USD 2.86 billion by 2030 and expand at a CAGR of 12.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increase in technological advancement in carrier screening along with the rising adoption of in vitro fertilization in emerging markets is expected to boost the market growth during the forecast period. The carrier receives the abnormal gene from the parents. Disorders such as sickle cell anemia, cystic fibrosis, Tay-Sachs disease, fragile X syndrome, and SMA can be identified using carrier screening.

Molecular tests are performed to detect the mutation by finding the abnormalities in the DNA. Next-generation sequencing is one of the techniques to perform tests. There is the possibility of the carrier not showing any symptoms and signs of illness. The test is recommended for pregnant women to check whether the baby will have a chance of genetic deformities. It is also advised to the male parent of the child to undergo the carrier screening test. The early-stage disease diagnosis and restraint of these genetic deformities is expected to augment the market growth. The test involves the tissue cells of the cheeks, blood, or saliva samples.

The adoption of carrier screening in the precision medicine market is also increasing. According to the article published in November 2022, by The Medical Journal of Australia, stated that the rapid innovations in genomic medicine along with sequencing technology for genetic code created a lucrative opportunity for genetic carrier screening. For incorporating population screening into precision medicine, a framework such as RE-AIM can be employed to plan research, assess barriers, and evaluates the result. This strategy was employed to assess the population DNA screening in the U.S.

The growing strategic initiatives by hospitals and regulatory bodies to increase the accessibility of carrier screening are expected to support market growth. For instance, in June 2022, NHS announced the expansion of BRCA genetic testing for the Jewish community. Since, 1 in 40 Jews is reported to be the carrier of BRCA, which increases the probability of certain cancers. Similarly, in June 2022, UnitedHealthcare Community proposed to introduce a coverage program for Ashkenazi Jewish Carrier Screening in the U.S.

On the other hand, limited implementation of public health screening, lack of genomic knowledge for reproductive health and primary care, and cost of genomic tests in the emerging market are expected to hamper the market growth. In India, the cost of carrier genetic screening ranges from USD 218 to USD 290. Considering the average purchasing power in the region, the cost is high for the majority of the population.

Carrier Screening Market Report Highlights

  • By type, the expanded carrier screening segment is projected to establish the fastest growth rate over the forecast period. Since increasing product development by the existing players to expand the usage of screening in various fields, such as precision medicine and IVF.
  • By medical condition, the Cystic fibrosis segment is anticipated to have a significant growth rate with a considerable market share in 2022. Owing to the increase in the disease incidence rate and carrier frequency. The product development by the players is likely to support the growth of the segment.
  • By technology, the DNA sequencing segment is anticipated to have the fastest-growing CAGR between 2023 and 2030. The adoption of NGS technology for prenatal diagnostics is considered to be the key driver.
  • By end-user, the laboratory segment is projected to have a majority of the market share in 2022. This is attributed to the presence of well-equipped facilities in developed countries, along with the increasing tests in the rural areas of emerging markets.
  • North America has strengthened its regional position in the market with 40.19% of the overall market share. This is attributed to the presence of hospitals and reference labs, along with the existence of key players in the region.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Research Methodology
1.1 Country Wise Market: Base Estimates
1.2 Global Market: CAGR Calculation
1.3 Region-Based Segment Share Calculation
1.4 Research Scope & Assumptions
1.5 List of Data Sources
1.5.1 Data for primary interviews, by sources
1.5.2 Data for primary interviews, by region
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Carrier Screening Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing adoption of IVF and cryopreservation
3.2.2 Technology advancement in screening techniques
3.2.3 Rising awareness in the emerging market
3.3 Market Restraint Analysis
3.3.1 Limited implementation of public health screening
3.4 Carrier screening - SWOT Analysis, By Factor (political & legal, economic, and technological)
3.5 Industry Analysis - Porter’s
3.6 Carrier Screening Market: Market Position Analysis, 2022
3.7 COVID-19 Impact Analysis
Chapter 4 Carrier Screening Market: Type Estimates & Trend Analysis
4.1 Carrier screening Market: Type Movement Analysis
4.2 Expanded carrier screening
4.2.1 Expanded carrier screening market
4.3 Targeted disease carrier screening
4.3.1 Targeted disease carrier screening market
Chapter 5 Carrier Screening Market: Medical Conditions Estimates & Trend Analysis
5.1 Carrier Screening Market: Medical Conditions Movement Analysis
5.2 Cystic fibrosis
5.2.1 Cystic fibrosis market
5.3 Tay-Sachs
5.3.1 Tay-Sachs market
5.4 Gaucher disease
5.4.1 Gaucher disease market
5.5 Sickle cell disease
5.5.1 Sickle cell disease market
5.6 Spinal muscular atrophy
5.6.1 Spinal muscular atrophy market
5.7 Other
5.7.1 Other market
Chapter 6 Carrier screening Market: Technology Estimates & Trend Analysis
6.1 Carrier screening Market: Technology Movement Analysis
6.2 DNA sequencing
6.2.1 DNA sequencing market
6.3 Polymerase chain reaction
6.3.1 Polymerase chain reaction market
6.4 Microarrays
6.4.1 Microarrays market
6.5 Other
6.5.1 Other market
Chapter 7 Carrier screening Market: End-user Estimates & Trend Analysis
7.1 Carrier screening Market: End-user Movement Analysis
7.2 Hospitals
7.2.1 Hospitals market
7.3 Laboratories
7.3.1 Laboratories market
7.4 Physician offices & clinics
7.4.1 Physician offices & clinics market
7.5 Other
7.5.1 Other market
Chapter 8 Carrier screening Market: Regional Estimates & Trend Analysis, by Type, Medical Condition, Technology, End-user
8.1 Carrier Screening Market Share By Region, 2022 & 2030
8.2 North America
8.2.1 SWOT Analysis
8.2.1.1 North America carrier screening market, by type
8.2.1.2 North America carrier screening market, by medical condition
8.2.1.3 North America carrier screening market, by technology
8.2.1.4 North America carrier screening market, by end-user
8.2.2 U.S.
8.2.2.1 Key Country Dynamics
8.2.2.2 Target Disease Prevalence
8.2.2.3 Competitive Scenario
8.2.2.4 Regulatory Framework
8.2.2.5 Reimbursement Scenario
8.2.2.6 U.S. carrier screening market, by type
8.2.2.7 U.S. carrier screening market, by medical condition
8.2.2.8 U.S. carrier screening market, by technology
8.2.2.9 U.S. carrier screening market, by end-user
8.2.3 Canada
8.2.3.1 Key Country Dynamics
8.2.3.2 Target Disease Prevalence
8.2.3.3 Competitive Scenario
8.2.3.4 Regulatory Framework
8.2.3.5 Reimbursement Scenario
8.2.3.6 Canada carrier screening market, by type
8.2.3.7 Canada carrier screening market, by medical condition
8.2.3.8 Canada carrier screening market, by technology
8.2.3.9 Canada carrier screening market, by end-user
8.3 Europe
8.3.1 SWOT Analysis
8.3.1.1 Europe carrier screening market, by type
8.3.1.2 Europe carrier screening market, by medical condition
8.3.1.3 Europe carrier screening market, by technology
8.3.1.4 Europe carrier screening market, by end-user
8.3.2 Germany
8.3.2.1 Key Country Dynamics
8.3.2.2 Target Disease Prevalence
8.3.2.3 Competitive Scenario
8.3.2.4 Regulatory Framework
8.3.2.5 Reimbursement Scenario
8.3.2.6 Germany carrier screening market, by type
8.3.2.7 Germany carrier screening market, by medical condition
8.3.2.8 Germany carrier screening market, by technology
8.3.2.9 Germany carrier screening market, by end-user
8.3.3 U.K.
8.3.3.1 Key Country Dynamics
8.3.3.2 Target Disease Prevalence
8.3.3.3 Competitive Scenario
8.3.3.4 Regulatory Framework
8.3.3.5 Reimbursement Scenario
8.3.3.6 U.K. carrier screening market, by type
8.3.3.7 U.K. carrier screening market, by medical condition
8.3.3.8 U.K. carrier screening market, by technology
8.3.3.9 U.K. carrier screening market, by end-user
8.3.4 France
8.3.4.1 Key Country Dynamics
8.3.4.2 Target Disease Prevalence
8.3.4.3 Competitive Scenario
8.3.4.4 Regulatory Framework
8.3.4.5 Reimbursement Scenario
8.3.4.6 France carrier screening market, by type
8.3.4.7 France carrier screening market, by medical condition
8.3.4.8 France carrier screening market, by technology
8.3.4.9 France carrier screening market, by end-user
8.3.5 Italy
8.3.5.1 Key Country Dynamics
8.3.5.2 Target Disease Prevalence
8.3.5.3 Competitive Scenario
8.3.5.4 Regulatory Framework
8.3.5.5 Reimbursement Scenario
8.3.5.6 Italy carrier screening market, by type
8.3.5.7 Italy carrier screening market, by medical condition
8.3.5.8 Italy carrier screening market, by technology
8.3.5.9 Italy carrier screening market, by end-user
8.3.6 Spain
8.3.6.1 Key Country Dynamics
8.3.6.2 Target Disease Prevalence
8.3.6.3 Competitive Scenario
8.3.6.4 Regulatory Framework
8.3.6.5 Reimbursement Scenario
8.3.6.6 Spain carrier screening market, by type
8.3.6.7 Spain carrier screening market, by medical condition
8.3.6.8 Spain carrier screening market, by technology
8.3.6.9 Spain carrier screening market, by end-user
8.3.7 Denmark
8.3.7.1 Key Country Dynamics
8.3.7.2 Target Disease Prevalence
8.3.7.3 Competitive Scenario
8.3.7.4 Regulatory Framework
8.3.7.5 Reimbursement Scenario
8.3.7.6 Denmark carrier screening market, by type
8.3.7.7 Denmark carrier screening market, by medical condition
8.3.7.8 Denmark carrier screening market, by technology
8.3.7.9 Denmark carrier screening market, by end-user
8.3.8 Sweden
8.3.8.1 Key Country Dynamics
8.3.8.2 Target Disease Prevalence
8.3.8.3 Competitive Scenario
8.3.8.4 Regulatory Framework
8.3.8.5 Reimbursement Scenario
8.3.8.6 Sweden carrier screening market, by type
8.3.8.7 Sweden carrier screening market, by medical condition
8.3.8.8 Sweden carrier screening market, by technology
8.3.8.9 Sweden carrier screening market, by end-user
8.3.9 Norway
8.3.9.1 Key Country Dynamics
8.3.9.2 Target Disease Prevalence
8.3.9.3 Competitive Scenario
8.3.9.4 Regulatory Framework
8.3.9.5 Reimbursement Scenario
8.3.9.6 Norway carrier screening market, by type
8.3.9.7 Norway carrier screening market, by medical condition
8.3.9.8 Norway carrier screening market, by technology
8.3.9.9 Norway carrier screening market, by end-user
8.4 Asia Pacific
8.4.1 SWOT Analysis
8.4.1.1 Asia Pacific carrier screening market, by type
8.4.1.2 Asia Pacific carrier screening market, by medical condition
8.4.1.3 Asia Pacific carrier screening market, by technology
8.4.1.4 Asia Pacific carrier screening market, by end-user
8.4.2 Japan
8.4.2.1 Key Country Dynamics
8.4.2.2 Target Disease Prevalence
8.4.2.3 Competitive Scenario
8.4.2.4 Regulatory Framework
8.4.2.5 Reimbursement Scenario
8.4.2.6 Japan carrier screening market, by type
8.4.2.7 Japan carrier screening market, by medical condition
8.4.2.8 Japan carrier screening market, by technology
8.4.2.9 Japan carrier screening market, by end-user
8.4.3 China
8.4.3.1 Key Country Dynamics
8.4.3.2 Target Disease Prevalence
8.4.3.3 Competitive Scenario
8.4.3.4 Regulatory Framework
8.4.3.5 Reimbursement Scenario
8.4.3.6 China carrier screening market, by type
8.4.3.7 China carrier screening market, by medical condition
8.4.3.8 China carrier screening market, by technology
8.4.3.9 China carrier screening market, by end-user
8.4.4 India
8.4.4.1 Key Country Dynamics
8.4.4.2 Target Disease Prevalence
8.4.4.3 Competitive Scenario
8.4.4.4 Regulatory Framework
8.4.4.5 Reimbursement Scenario
8.4.4.6 India carrier screening market, by type
8.4.4.7 India carrier screening market, by medical condition
8.4.4.8 India carrier screening market, by technology
8.4.4.9 India carrier screening market, by end-user
8.4.5 South Korea
8.4.5.1 Key Country Dynamics
8.4.5.2 Target Disease Prevalence
8.4.5.3 Competitive Scenario
8.4.5.4 Regulatory Framework
8.4.5.5 Reimbursement Scenario
8.4.5.6 South Korea carrier screening market, by type
8.4.5.7 South Korea carrier screening market, by medical condition
8.4.5.8 South Korea carrier screening market, by technology
8.4.5.9 South Korea carrier screening market, by end-user
8.4.6 Australia
8.3.9.1 Key Country Dynamics
8.4.6.2 Target Disease Prevalence
8.4.6.3 Competitive Scenario
8.4.6.4 Regulatory Framework
8.4.6.5 Reimbursement Scenario
8.4.6.6 Australia carrier screening market, by type
8.4.6.7 Australia carrier screening market, by medical condition
8.4.6.8 Australia carrier screening market, by technology
8.4.6.9 Australia carrier screening market, by end-user
8.4.7 Thailand
8.4.7.1 Key Country Dynamics
8.4.7.2 Target Disease Prevalence
8.4.7.3 Competitive Scenario
8.4.7.4 Regulatory Framework
8.4.7.5 Reimbursement Scenario
8.4.7.6 Thailand carrier screening market, by type
8.4.7.7 Thailand carrier screening market, by medical condition
8.4.7.8 Thailand carrier screening market, by technology
8.4.7.9 Thailand carrier screening market, by end-user
8.5 Latin America
8.5.1 SWOT Analysis
8.5.1.1 Latin America carrier screening market, by type
8.5.1.2 Latin America carrier screening market, by medical condition
8.5.1.3 Latin America carrier screening market, by technology
8.5.1.4 Latin America carrier screening market, by end-user
8.5.2 Brazil
8.5.2.1 Key Country Dynamics
8.5.2.2 Target Disease Prevalence
8.5.2.3 Competitive Scenario
8.5.2.4 Regulatory Framework
8.5.2.5 Reimbursement Scenario
8.5.2.6 Brazil carrier screening market, by type
8.5.2.7 Brazil carrier screening market, by medical condition
8.5.2.8 Brazil carrier screening market, by technology
8.5.2.9 Brazil carrier screening market, by end-user
8.5.3 Mexico
8.5.3.1 Key Country Dynamics
8.5.3.2 Target Disease Prevalence
8.5.3.3 Competitive Scenario
8.5.3.4 Regulatory Framework
8.5.3.5 Reimbursement Scenario
8.5.3.6 Mexico carrier screening market, by type
8.5.3.7 Mexico carrier screening market, by medical condition
8.5.3.8 Mexico carrier screening market, by technology
8.5.3.9 Mexico carrier screening market, by end-user
8.5.4 Argentina
8.5.4.1 Key Country Dynamics
8.5.4.2 Target Disease Prevalence
8.5.4.3 Competitive Scenario
8.5.4.4 Regulatory Framework
8.5.4.5 Reimbursement Scenario
8.5.4.6 Argentina carrier screening market, by type
8.5.4.7 Argentina carrier screening market, by medical condition
8.5.4.8 Argentina carrier screening market, by technology
8.5.4.9 Argentina carrier screening market, by end-user
8.6 MEA
8.6.1 SWOT Analysis
8.6.1.1 MEA carrier screening market, by type
8.6.1.2 MEA carrier screening market, by medical condition
8.6.1.3 MEA carrier screening market, by technology
8.6.1.4 MEA carrier screening market, by end-user
8.6.2 South Africa
8.6.4.1 Key Country Dynamics
8.6.2.2 Target Disease Prevalence
8.6.2.3 Competitive Scenario
8.6.2.4 Regulatory Framework
8.6.2.5 Reimbursement Scenario
8.6.2.6 Argentina carrier screening market, by type
8.6.2.7 Argentina carrier screening market, by medical condition
8.6.2.8 Argentina carrier screening market, by technology
8.6.2.9 Argentina carrier screening market, by end-user
8.6.3 Saudi Arabia
8.6.3.1 Key Country Dynamics
8.6.3.2 Target Disease Prevalence
8.6.3.3 Competitive Scenario
8.6.3.4 Regulatory Framework
8.6.3.5 Reimbursement Scenario
8.6.3.6 Saudi Arabia carrier screening market, by type
8.6.3.7 Saudi Arabia carrier screening market, by medical condition
8.6.3.8 Saudi Arabia carrier screening market, by technology
8.6.3.9 Saudi Arabia carrier screening market, by end-user
8.6.4 UAE
8.6.4.1 Key Country Dynamics
8.6.4.2 Target Disease Prevalence
8.6.4.3 Competitive Scenario
8.6.4.4 Regulatory Framework
8.6.4.5 Reimbursement Scenario
8.6.4.6 UAE carrier screening market, by type
8.6.4.7 UAE carrier screening market, by medical condition
8.6.4.8 UAE carrier screening market, by technology
8.6.4.9 UAE carrier screening market, by end-user
8.6.5 Kuwait
8.6.5.1 Key Country Dynamics
8.6.5.2 Target Disease Prevalence
8.6.5.3 Competitive Scenario
8.6.5.4 Regulatory Framework
8.6.5.5 Reimbursement Scenario
8.6.5.6 Kuwait carrier screening market, by type
8.6.5.7 Kuwait carrier screening market, by medical condition
8.6.5.8 Kuwait carrier screening market, by technology
8.6.5.9 Kuwait carrier screening market, by end-user
Chapter 9 Competitive Landscape
9.1 Participant’s overview
9.2 Financial performance
9.3 Participant categorization
9.3.1 Market leaders
9.3.1.1 Carrier screening market share analysis, 2022
9.3.1.2 Company profiles
9.3.1.2.1 Thermo Fisher Scientific Inc.
9.3.1.2.2 Myriad Genetics, Inc.
9.3.1.2.3 Cepheid
9.3.1.2.4 Laboratory Corporation of America Holdings
9.3.1.2.5 Otogenetics
9.3.1.2.6 Illumina Inc.
9.3.1.2.7 MedGenome
9.3.1.2.8 GeneTech
9.3.1.2.9 Centogene N.V.
9.3.1.2.10 F. Hoffman-La Roche Limited
9.3.2 Strategy mapping
9.3.2.1 Expansion
9.3.2.2 Acquisition
9.3.2.3 Collaborations
9.3.2.4 Product/service launch
9.3.2.5 Partnerships
9.3.2.6 Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings